Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) and Ginkgo Bioworks (NYSE:DNA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.
Valuation and Earnings
This table compares Adaptive Biotechnologies and Ginkgo Bioworks”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adaptive Biotechnologies | $177.28 million | 3.90 | -$225.25 million | ($1.34) | -3.49 |
| Ginkgo Bioworks | $251.46 million | 1.40 | -$892.87 million | ($13.08) | -0.48 |
Adaptive Biotechnologies has higher earnings, but lower revenue than Ginkgo Bioworks. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adaptive Biotechnologies | 0 | 1 | 3 | 0 | 2.75 |
| Ginkgo Bioworks | 3 | 1 | 1 | 0 | 1.60 |
Adaptive Biotechnologies currently has a consensus target price of $6.50, indicating a potential upside of 38.89%. Ginkgo Bioworks has a consensus target price of $4.58, indicating a potential downside of 27.73%. Given Adaptive Biotechnologies’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Adaptive Biotechnologies is more favorable than Ginkgo Bioworks.
Profitability
This table compares Adaptive Biotechnologies and Ginkgo Bioworks’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adaptive Biotechnologies | -110.13% | -62.06% | -26.82% |
| Ginkgo Bioworks | -298.78% | -58.54% | -34.24% |
Insider and Institutional Ownership
99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 6.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
Adaptive Biotechnologies has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.
Summary
Adaptive Biotechnologies beats Ginkgo Bioworks on 10 of the 14 factors compared between the two stocks.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
